Table 3.
Stereotactic body radiation therapy studies.
| Study | N | Risk group (% of sample size) | Total dose (Gy) | Fraction size (Gy) | Median follow-up (months) | Biochemical control (%) | Grade 3+ GI toxicity |
|---|---|---|---|---|---|---|---|
| Katz (3) | 304 | LR 69 | 35–36.25 | 7–7.25 | 60 | LR 97 | 0% |
| IR 27 | IR 90.7 | ||||||
| HR 4 | HR 74.1 | ||||||
| King (4) | 1100 | LR 58 | 35–40 | 7–8 | 36 | LR 95 | NR |
| IR 30 | IR 83 | ||||||
| HR 11 | HR 78 | ||||||
| McBride (5) | 45 | LR 100 | 36.25–37.5 | 7.25–7.5 | 44.5 | 97.7 | 5% |
| Oliai(6) | 70 | LR 51 | 35–37.5 | 7–7.5 | 27–33 | LR 100 | 0% |
| IR 31 | IR 95 | ||||||
| HR 17 | HR 77.1 | ||||||
| Chen (7) | 100 | LR 37 | 35–36.25 | 7–7.25 | 27.6 | 99 | 0% |
| IR 55 | |||||||
| HR 8 | |||||||
| This study | 91 | LR 36 | 45–50 | 9–10 | 42 | LR 100 | 6.6% |
| IR 64 | IR 98 | ||||||
| All 99 | |||||||
| 30 | LR 37 | 45–47.5 | 9–9.5 | 54 | 96.7 | 0% | |
| IR 63 | |||||||
| 61 | LR 36 | 50 | 10 | 24.5 | 100 | 9.8% | |
| IR 64 |
LR, low risk; IR, intermediate risk; HR, high risk; GI, gastrointestinal.